magistrsko delo
Jan Slunečko (Author), Mojca Narat (Reviewer), Tatjana Avšič-Županc (Mentor), Miša Korva (Co-mentor)

Abstract

Bolezen COVID-19 je posledica okužbe z virusom SARS-CoV-2 pri ljudeh. Bolezen poteka raznoliko: od poteka bolezni brez kliničnih znakov, do kritične oblike, ki lahko privede do smrti. Glavni klinični znaki pri COVID-19 so vročina, kašelj in utrujenost, neredko pa se pojavlja tudi oteženo dihanje in tesnoba v prsih. V magistrski nalogi smo preiskovali morebitno vzročno povezavo med kliničnim potekom COVID-19 in specifičnim imunskim odzivom gostitelja na posamezne virusne beljakovine (N, S1, S2 in RBD). Dodatno nas je zanimalo tudi, ali potek bolezni (blažji, zmeren, resen ali kritičen) vpliva na koncentracijo protiteles proti posameznim virusnim beljakovinam in/ali na dinamiko protitelesnega imunskega odziva. V raziskavo smo vključili 79 bolnikov s COVID-19. Ugotovili smo, da ima v prvem vzorcu, ki je bil v povprečju odvzet v dveh tednih po dokazu okužbe s SARS-CoV-2, 64,6 % bolnikov protitelesa razreda IgG, 79,7 % bolnikov protitelesa razreda IgA in 60,8 % bolnikov protitelesa razreda IgM. Prav tako smo ugotovili, da se vsa protitelesa pojavijo že zelo zgodaj po okužbi in da najverjetneje jakost protitelesnega odziva vpliva na težo poteka bolezni. Ugotovili smo, da koncentracija protiteles proti RBD in N lahko vpliva na potek bolezni. Pri večini protiteles, glede na posamezne virusne epitope, nismo ugotovili razlike v dinamiki. Pričakovano dinamiko protiteles smo dokazali v primeru protiteles razreda IgA, usmerjenih proti virusni beljakovini N. Dodatno smo dokazali, da imata na potek bolezni in klinično sliko poleg jakosti imunskega odziva velik vpliv tudi spol in starost.

Keywords

virusi;koronavirusi;SARS-CoV-2;COVID-19;jakost imunskega odziva;resnost klinične slike;beljakovina bodice;podenota S1 beljakovine bodice;podenota S2 beljakovine bodice;nukleokapsidna beljakovina;receptor vezavna domena;imunski odziv;

Data

Language: Slovenian
Year of publishing:
Typology: 2.09 - Master's Thesis
Organization: UL MF - Faculty of Medicine
Publisher: [J. Slunečko]
UDC: 606:616-022.6:57.083:616-097.3(043.2)
COBISS: 75589891 Link will open in a new window
Views: 477
Downloads: 4
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: English
Secondary title: Characterization of antibody immune response in patients with COVID-19
Secondary abstract: SARS-CoV-2 virus is the causative agent of COVID-19. The disease progresses in a variety of ways. It varies from infection without clinical symptoms, to severe disease that can lead to death. The main clinical symptoms of COVID-19 are fever, cough, and fatigue, as well as shortness of breath and chest tightness. The aim of our study was to investigate the possible causal relationship between clinical manifestation of COVID-19 and the specific immune response to individual viral proteins (N, S1, S2 in RBD). In addition, we were interested in whether the course of the disease (mild, moderate, serious, or critical) is affected by the concentration of antibodies against individual viral proteins or the dynamic antibody immune response. The study included 79 patients with COVID-19. We found that in the first sample, which was on average obtained 2 weeks after a confirmed infection with SARS-CoV-2, 64.6% of patients had IgG antibodies, 79.7% of patients had IgA antibodies, and 60.8% had IgM antibodies against SASR-CoV-2. We also found that all antibodies appear soon after infection and that most likely the strength of the antibody response directly affects the severity of the disease. We found that the concentration of antibodies against RBD and N can affect the course of the disease. No differences in dynamics were found for most viral epitopes in most antibodies. The expected antibody dynamic was observed in the case of IgA antibodies specific against the N protein. Furthermore, we have shown that in addition to a strong immune response, gender and age also greatly impact the course of the disease and its clinical manifestation.
Secondary keywords: viruses;coronaviruses;strength of immune response;clinical severity;spike protein;S1 subunit of spike protein;S2 subunit of spike protein;nucleocapsid protein;receptor binding domain;immune response;
Type (COBISS): Master's thesis/paper
Study programme: 0
Embargo end date (OpenAIRE): 2022-09-02
Thesis comment: Univ. v Ljubljani, Biotehniška fak., Študij biotehnologije
Pages: X, 52 f., [31] f. pril.
ID: 13335654